Walton N Y, Gunawan S, Treiman D M
Neurology Service, Department of Veterans Affairs Medical Center, Los Angeles, California.
Epilepsy Res. 1994 Dec;19(3):237-44. doi: 10.1016/0920-1211(94)90067-1.
The potential clinical efficacy of tiagabine for control of status epilepticus was evaluated in an experimental model. Tiagabine was administered to cobalt-lesioned rats in which status epilepticus was induced by injection of homocysteine thiolactone. Tiagabine was effective in controlling status epilepticus in this model; the median effective dose for control of generalized tonic-clonic seizures in the model was 8.3 mg/kg. Tiagabine administration produced an abnormal, hypo-reactive behavioral state which was accompanied by an EEG pattern of high-amplitude, frontally dominant, rhythmic, 3-5-Hz spike-wave activity. This EEG and behavioral syndrome could be reproduced by administration of tiagabine to normal, non-epileptic rats. The exact nature of this syndrome remains unclear, but whether it is an epileptic or encephalopathic phenomenon, further study is clearly required before this drug should be considered for use in the treatment of human status epilepticus.
在一个实验模型中评估了噻加宾控制癫痫持续状态的潜在临床疗效。将噻加宾给予钴损伤大鼠，在这些大鼠中通过注射同型半胱氨酸硫内酯诱发癫痫持续状态。噻加宾在该模型中有效控制癫痫持续状态；该模型中控制全身强直阵挛性发作的半数有效剂量为8.3毫克/千克。给予噻加宾会产生一种异常的、反应低下的行为状态，同时伴有脑电图呈现高幅、额叶占优势、节律性的3 - 5赫兹棘波活动模式。通过对正常的、非癫痫大鼠给予噻加宾可重现这种脑电图和行为综合征。该综合征的确切性质仍不清楚，但无论它是癫痫性还是脑病性现象，在考虑将这种药物用于治疗人类癫痫持续状态之前显然需要进一步研究。
